- CNTX is trading 5% up today at $0.67 on bullish analyst sentiment and aggressive price targets, alongside its recent inclusion in the Russell 2000 and Russell 3000 Indexes.
- Analysts have issued Strong Buy ratings with price targets ranging from $4–$9, fueling speculative interest in the early-stage biopharmaceutical company.
- Context Therapeutics was added to the Russell 2000 and Russell 3000 Indexes, effective June 26, 2026, with the announcement made on July 6, 2026. This broadens potential ownership by index and benchmarked funds.